The Courtroom Battle Over How Fast Pharma Has to Invent
Can you sue a drug company for not inventing fast enough? The California Supreme Court just answered that question in a 6–1 ruling that wiped out 24,000 cases against Gilead and sent shockwaves through pharma's legal landscape.
Imagine suing Netflix because they didn't release a better show fast enough. Sounds absurd, right? That's roughly the argument the California Supreme Court just shut down, except the "show" was a safer HIV drug, and the stakes were the health of 24,000 patients.
On August 3, the court ruled 6–1 in favor of Gilead Sciences in a case that asked a question no court had ever squarely answered before: Can you sue a drug company for being too slow to develop a better medicine?
The answer, at least in California, is now a definitive no.
Two Drugs, One Very Expensive Grudge
To understand the case, you need to know about two molecules with very similar names and very different reputations.
TDF (tenofovir disoproxil fumarate) was Gilead's workhorse HIV drug for years. It worked well, but it came with baggage: kidney damage and bone loss in some patients. TAF (tenofovir alafenamide) was the newer sibling, designed to do the same job with fewer side effects.
Plaintiffs alleged that Gilead knew about TAF as early as 2004 and had evidence it would be safer. But instead of rushing TAF to market, they claimed Gilead shelved it. The motive, according to plaintiffs? Pure profit. Keep selling the older, more toxic TDF while its patents were still golden, then bring TAF to market just in time to "product hop" onto fresh patent protection.
The key wrinkle: nobody was calling TDF defective. Plaintiffs admitted the drug worked. They admitted its risks were properly disclosed on the label. Their argument was narrower and, in legal terms, unprecedented. They said Gilead owed patients a duty of reasonable care not to delay a safer alternative solely to maximize revenue.
Legal scholars called this the "duty to innovate" theory. And for a while, it looked like it might actually stick.
The Lower Court Said "Maybe"
In 2024, a California appeals court did something that sent shockwaves through pharma boardrooms. It ruled that Not because the existing drug was broken, but because a better option was sitting on a shelf gathering dust.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
if a manufacturer deliberately delays a safer drug design purely for profit, that could count as negligence.
That ruling was described as a first-of-its-kind decision. Roughly 24,000 patients had consolidated their cases in California state court, and suddenly, the door was open.
Gilead, understandably, was not thrilled. Neither was the rest of the pharmaceutical industry. The implications were enormous: if this legal theory survived, any company exploring a next-generation drug could face lawsuits for not bringing it to market quickly enough.
Think of it like this. You're a chef with a great pasta recipe. You start experimenting with a new sauce in the back kitchen. Under this legal theory, a customer who preferred the old sauce could sue you for not serving the new one sooner. The fact that the old pasta was perfectly fine wouldn't matter.
Gilead appealed to the California Supreme Court.
The Supreme Court Slams the Door
Justice Joshua Groban, writing for the six-justice majority, didn't mince words. The court declined to recognize "for the first time anywhere" a sweeping form of liability for injuries caused by a non-defective drug based on the manufacturer's failure to bring a different drug to market sooner.
The majority raised several concerns about what would happen if this theory became law:
It "lacks a clear limiting principle." Where would the line be? Could patients sue every time a company pauses a clinical program?
It would "invite fact finders to second-guess complex resource-allocation decisions" that involve science, regulation, manufacturing, and capital deployment.
It would create "substantial burdens" and risk "adverse consequences for pharmaceutical innovation, public health, and patient safety."
That last point is the one the industry is latching onto. The court essentially said: if you force companies to fear lawsuits over R&D timing, they might stop exploring improvements altogether. Why poke around with a potentially safer version of Drug A if that research could later be used as ammunition in a negligence suit?
The court ordered the lower court to grant summary judgment for Gilead on all claims. Just like that, roughly 23,000 consolidated cases were effectively dead.
The Lone Dissent
Justice Kelli Evans wasn't buying it. In her dissent, she warned that the ruling gives manufacturers "sweeping immunity from negligence liability" when they have information suggesting a safer alternative exists and yet choose to delay.
It's a fair point, and it highlights the tension at the heart of this case. On one side: protecting companies' freedom to manage complex R&D portfolios without constant legal second-guessing. On the other: holding powerful corporations accountable when profit motives appear to override patient welfare.
The majority acknowledged the tension but landed firmly on the side of discretion. When an alleged safer drug hasn't even completed large-scale trials or received FDA approval, the court noted, any claim of "harm" from delay depends on a chain of uncertain scientific outcomes and decisions by regulators the company doesn't control.
Why Pharma Is Popping Champagne
This ruling doesn't just help Gilead. It sends a signal to every drug company managing a pipeline with first-generation and next-generation products sitting side by side.
Consider how drug development actually works. A company might have a blockbuster on the market generating billions in revenue. Meanwhile, in the labs, scientists are tinkering with a potentially better version. The timeline from early research to FDA approval can stretch 10 to 15 years and cost billions. Along the way, candidates fail, trials get delayed, regulators ask for more data, and manufacturing hits snags.
Under the plaintiffs' theory, any documented work on that next-gen candidate could become Exhibit A in a future lawsuit alleging the company didn't move fast enough. That's the scenario pharma's lawyers have been losing sleep over since the lower court's ruling.
Gilead's legal counsel at Orrick called the decision a "landmark product liability decision." The Wall Street Journal's editorial board, which had weighed in during briefing, had previously argued the plaintiffs' theory would create "a disincentive to innovate."
From a financial perspective, the ruling eliminates a massive litigation overhang for Gilead specifically. And it comes on the heels of another legal win: the reversal of a $1.2 billion patent award in a CAR-T therapy dispute with Bristol Myers Squibb's Juno unit. Gilead's legal fortunes are looking decidedly sunnier.
The Bigger Picture: What This Doesn't Change
Let's be clear about what this ruling does not do.
It does not give pharma companies a free pass to sell dangerous drugs. Traditional product liability is fully intact. If a drug is defectively designed, poorly manufactured, or inadequately labeled, companies can still be sued into oblivion.
It does not address antitrust concerns. The FTC's ongoing crackdown on "pay-for-delay" deals (where brand-name companies pay generic makers to stay off the market) is a separate legal universe. Same goes for patent strategies that extend monopoly pricing.
And it does not resolve the separate federal litigation over Gilead's TDF/TAF saga. Gilead previously settled a federal case involving about 2,600 patients for $40 million, without admitting wrongdoing. The state-court cases were the much larger batch, and those are the ones this ruling wipes out.
The ruling also only directly governs California state law. But California's outsized influence in tort law (and its sheer population) means other states will almost certainly look to this decision when similar theories arise. No jurisdiction had recognized a "duty to innovate" before, and now the nation's largest state has explicitly refused to be the first.
So Who Really Wins?
The honest answer: it's complicated.
Pharma executives win flexibility. They can manage pipeline transitions, park early-stage programs, and sequence launches without a new category of negligence lawsuits hanging over every decision.
Investors win clarity. Reduced litigation tail risk makes cash flows from first-generation drugs more predictable, which supports the economics of funding high-risk pipeline bets.
Patients, though, are left with fewer tools to hold companies accountable for decisions that look, at least from the outside, like profit over people. The 24,000 plaintiffs who suffered kidney injuries and bone loss from TDF won't get their day in court on the "duty to innovate" theory.
The tension isn't going away. Legislators and regulators may try to fill the gap with statutory requirements or policy reforms. But for now, the message from California's highest court is unmistakable: how fast a company invents is not something a jury gets to decide.
Clinical & Regulatory5 min read
A Virus That Killed 100% of Bladder Cancers in a Small Trial
ImmVira's oncolytic virus MVR-T3011 just posted a 100% complete response rate in bladder carcinoma in situ at 9 months. The catch? The cohort is tiny. Here's why urologists are watching closely anyway.
